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Escitalopram is the most selective of the serotonin reuptake inhibitor (SSRI) antidepressants.
We conducted a meta-analysis of placebo-controlled studies where escitalopram was used to
treat patients with social anxiety disorder (SAD). Data from all randomised, double-blind
placebo-controlled studies in SAD with escitalopram from both specialist settings and general
practice were used. Patients met the DSM-IV criteria for SAD, were Z18 years old, and had a
Liebowitz Social Anxiety Scale (LSAS) Z60. The primary outcome measure was the estimated
treatment difference in LSAS total score at Week 12. Secondary outcome measures included the
estimated treatment difference in the Clinical Global Impression-Severity (CGI-S) score at Week
12. A total of 1598 patients from 3 randomised controlled trials were included in the analyses.
Escitalopram (n=1061) was superior to placebo (n=537), with an estimated treatment
difference on the LSAS of 9.2 points (95%CI: [14.4; 4.0], po0.01) (escitalopram 5 mg/
day), 4.6 points (95%CI: [8.1; 1.0], po0.01) (escitalopram 10 mg/day), 10.1 points
(95%CI: [13.7; 6.5], po0.01) (escitalopram 20 mg/day) and 7.3 points (95%CI: [12.3;
2.2], po0.01) (escitalopram 10-20 mg/day). For the CGI-S, the corresponding values were
0.55 points (95%CI: [0.79; 0.31], po0.01) (escitalopram 5 mg/day), 0.26 points (95%CI:
[0.42; 0.10], po0.01) (escitalopram 10 mg/day), 0.48 points (95%CI: [0.64; 0.31],
po0.01) (escitalopram 20 mg/day) and 0.29 points (95%CI: [0.51; 0.07], po0.05)
(escitalopram 10-20 mg/day). The withdrawal rate due to adverse events was 7.2% foro.2016.02.013
blished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/4.0/).
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Table 1 Overview of studies in
Study no. (reference) D
1 Lader et al. (2004) 2
2 Kasper et al. (2005) 1
3 Asakura et al. (2016a) 1
ESC: escitalopram; LOCF: last obse
aChange from baseline to primar
bData from primary endpoint at
1063Efﬁcacy of escitalopram in the treatment of social anxiety disorderescitalopram, compared with 4.3% for placebo (po0.05). In this meta-analysis, all doses of
escitalopram showed signiﬁcant superiority in efﬁcacy versus placebo in the treatment of
patients with SAD.
Crown Copyright & 2016 Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Social anxiety disorder (SAD) is typically a long-term
medical condition with an estimated 1-year prevalence of
1.1–4.4% (Wittchen et al., 2011) or around 4.5% (Kessler
et al., 2005), and a lifetime prevalence of 12.1% (Kessler
et al., 2005) with an onset of symptoms typically in
adolescence. This leads to signiﬁcant functional impair-
ment, including occupational, academic, and social dys-
function (de Menezes et al., 2011). SAD comprises social
interaction fears, observation fears and public speaking
fears. Early treatment is recommended, given the pro-
longed course of the disease and the low rate of sponta-
neous remission (Baldwin et al., 2014; Nagata et al., 2015).
Escitalopram is the most selective of the serotonin
reuptake inhibitor (SSRI) antidepressants (Owens et al.,
2001) and its efﬁcacy has been demonstrated in SAD and
other indications in both primary care and specialist settings
(Kennedy et al., 2009). The efﬁcacy of escitalopram,
together with its good tolerability (Baldwin et al., 2007),
suggests a favourable beneﬁt-risk ratio.
To investigate the efﬁcacy of the approved doses of
escitalopram, the present analysis examined data from
three randomised, double-blind placebo-controlled SAD
studies. Meta-analysis is a method to synthesise data from
several clinical studies providing they have similar trial
designs, rating scales, duration, and patient selection
criteria. When patient-level data are not available a
meta-analysis uses the study as the unit of observation to
produce a weighted average of trial results. The authors
searched for all published and unpublished randomised
placebo-controlled studies in SAD up to October 2015
involving escitalopram.cluded in the meta-analysis.
uration Design
4 weeksb Fixed
PBO
2 weeks Flexible
PBO
2 weeks Fixed
PBO
rvation carried forward; LSAS: Lie
y endpoint (ANCOVA, LOCF, FAS).
Week 12.2. Experimental procedures
In this meta-analysis of published studies of the escitalopram
treatment of patients with SAD, an attempt was made to identify
all randomised, double blind placebo-controlled studies, regardless
of patient numbers or treatment length.
2.1. Sources of data and criteria for review
Multiple computer searches using MEDLINE (1966-Oct 2015), EMBASE
(1998–2015), and the Cochrane Collaboration (1980–Oct 2015) were
conducted. The authors speciﬁed the keywords, including escitalo-
pram, placebo, randomized controlled trials, and social anxiety
disorder. Additional studies in any language were sought in reference
lists of retrieved articles. Unpublished trials were identiﬁed through
the Controlled Trials database and the National Institute of Health's
Computer Retrieval of Information on Scientiﬁc Projects (CRISP)
service (1972–2015). In addition, the following clinical trial registration
sites were searched: www.lundbecktrials.com, www.forestclinical
trials.com, www.japic.or.jp, www.clinicaltrials.gov, www.clinicaltrial
results.org, www.ifpma.org/clinicaltrials and www.controlled-trials.
com. Results from all three of these studies have already been
published (Lader et al., 2004; Kasper et al., 2005; Asakura et al.,
2016a).
2.2. Patients
Patients were randomly assigned to double-blind treatment at the
daily dosages shown in Table 1. Eligible patients fulﬁlled the DSM-IV
criteria for a primary diagnosis of generalised SAD and were at least 18
years old. Patients were required to have a baseline LSAS score Z70
(Lader et al., 2004; Kasper et al., 2005) or an LSAS-J Z60 (the LSAS-J
is the Japanese translation of the LSAS) and a Clinical Global
Impression-Severity (CGI-S) score Z4 (Kasper et al., 2005; Asakura
et al., 2016a). Patients were excluded if their baseline MontgomeryESC dose Baseline LSAS ΔLSASa FAS (n)
5 mg 94.3 38.7 166
10 mg 92.4 34.6 163
20 mg 94.0 39.8 164
– 96.0 29.5 165
10–20 mg 96.3 34.5 177
– 95.4 27.2 176
10 mg 94.5 26.9 198
20 mg 93.4 32.6 193
– 95.3 23.1 196
bowitz Social Anxiety Scale; PBO: placebo, FAS: full analysis set.
Table 2 Baseline characteristics of the APTS population in the meta-analysis.
Lader et al. (2004) Kasper et al. (2005) Asakura et al. (2016a)
Placebo Escitalopram 5, 10 &
20 mg
Placebo Escitalopram 10–
20 mg
Placebo Escitalopram 10 &
20 mg
Patients (n) 166 504 177 181 196 391
Agea 37712 37711 36711 39711 33710 33710
Men (%) 81 (48.8%) 233 (46.2%) 94 (53.1%) 101 (56%) 87 (44.4%) 173 (44.2%)
Caucasian (%) 100 99.7 91.6 90.6 0 0
Japanese (%) 0 0 0 0 100 100
Age of SAD onset
(years)a
1878 1778 1578 1579 19710 1979
Duration of disorder
(years)a
19713 20712 21712 24713 14711 14710
LSAS total scorea 96.0714.4 93.6714.4 95.4716.4 96.3717.4 95.3718.5 94.0718.0
CGI-S total scorea 4.870.8 4.870.7 4.870.7 4.870.7 4.870.8 4.970.8
MADRS total scorea 7.674.8 7.074.4 7.574.4 7.674.5 3.674.0 3.873.9
amean7SD. APTS: all patients treated set; CGI-S: Clinical Global Impression-Severity, LSAS: Liebowitz Social Anxiety Scale,
MADRS: Montgomery Åsberg Depression Rating Scale SAD: social anxiety disorder, SD: standard deviation.
D.S. Baldwin et al.1064Åsberg Depression Rating Scale (MADRS) (Montgomery and Åsberg,
1979) total score was Z18 (Lader et al., 2004), MADRS 419 (Kasper
et al., 2005), or MADRS Z15 (Asakura et al., 2016a). Patients with a
serious concomitant illness or a recent history of alcohol or drug abuse
were excluded from study participation. Clinically signiﬁcant abnorm-
alities on the baseline physical examination, electrocardiogram, or
laboratory tests were also criteria for exclusion from study participa-
tion (Lader et al., 2004; Kasper et al., 2005). Patients who had a
known hypersensitivity to citalopram or escitalopram (Asakura et al.,
2016a) had taken disallowed recent or concomitant medication were
also excluded. Patients were excluded if they had been diagnosed with
another psychiatric disorder (mania, bipolar disorder, schizophrenia,
or any other psychotic disorder); if they were considered to be at
signiﬁcant risk of suicide; if they were unlikely to be able to comply
with the protocol; or if they had any disorder that might interfere with
study treatment or impair treatment compliance.
2.3. Variables
The primary efﬁcacy variable in each of the 3 studies was the LSAS.
The primary outcome endpoint of this meta-analysis was the
estimated difference to placebo in the LSAS total score at Week
12. A secondary outcome measure was the estimated difference to
placebo in the CGI-S score at Week 12 and response to treatment
(CGI-I score r2).
2.4. Statistical analyses
Meta-analyses were carried out by dose on three endpoints: change
from baseline to Week 12 on the symptom-speciﬁc LSAS scale (the
primary analysis in all three studies); change from baseline on the
Clinical Global Impression- Severity scale (CGI-S); as well as on
the binary endpoint response (CGI-I score r2). The treatment effects
and standard errors based on the pre-deﬁned adjusted analyses
reported by dose were used as inputs to the meta-analyses for the
continuous endpoint, while the raw unadjusted prevalences were used
for the binary response endpoint. Treatment estimates and conﬁdence
intervals are shown in tables and in forest plots with pooled estimates
by dose groups. Study-speciﬁc treatment effects were analysed and
tested for heterogeneity using chi-squared tests, in order to check if
the ﬁxed-effect model was adequate or if random-effect models had tobe used. The study-speciﬁc treatment effect test was not statistically
signiﬁcant and the pooled analyses were thus all conducted using ﬁxed-
effect models. These analyses used the statistical summary data from
each published study based on a modiﬁed intent-to-treat analysis (the
full-analysis set [FAS], using the last observation carried forward (LOCF)
method for missing data.
For all efﬁcacy measures, point estimates were expressed with
their 95% conﬁdence intervals (95% CI). The number needed to treat
(NNT) is the inverse of the difference in the proportion of patients
responding to treatment between escitalopram and placebo
rounded up to the nearest integer. Similarly, the limits of the NNT
conﬁdence intervals are the inverted limits of the conﬁdence
intervals of the difference in proportions. Statistical analyses were
performed using SAS software, and all statistical tests were two-
sided. The alpha risk was set to 5%. Disposition, safety and
tolerability data are presented for each study.
3. Results
A total of 1615 patients comprised the treated population of
the three studies [escitalopram (n=1076) and placebo
(n=539)] and 1598 (98.9%) were included in the intent-to-
treat (ITT) analysis of the efﬁcacy [escitalopram (n=1061) and
placebo (n=537)]. There was an approximately 1:1 distribu-
tion of men (44.8%) and women (55.2%). The patients had a
mean age of 36 years and an onset of SAD at approximately 18
years of age, with a mean duration of about 18 years. The
mean LSAS total score at baseline was 95.1, with a mean CGI-S
of 4.8 (indicating that the patients were markedly ill) and a
low level of depressive symptoms (mean MADRS total score of
6.1). All studies were randomised without stratiﬁcation, and
baseline scores were not statistically signiﬁcantly different
between treatment groups (Table 2).
3.1. Efﬁcacy at end of 12 weeks of double-blind
treatment
The overall difference in treatment effect was in favour of
escitalopram versus placebo at all doses, with an estimated
LSAS
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Figure 1 Estimated treatment difference in the Liebowitz Social Anxiety Scale (LSAS) total score at Week 12 (primary analysis) for
all 3 studies shown with 95% conﬁdence intervals. All of the tests for heterogeneity within dose are non-signiﬁcant (p40.05), so the
analysis is based on a ﬁxed effects model. Negative values are in favour of escitalopram, while positive values are in favour of
placebo. Patient numbers are shown for escitalopram (Esc) and placebo (Pbo).
1065Efﬁcacy of escitalopram in the treatment of social anxiety disordertreatment difference to placebo on the LSAS of 9.2 points
(95% CI: [14.4; 4.0], po0.01) (escitalopram 5 mg/day),
4.6 points (95%CI: [8.1; 1.0], po0.01) (escitalopram
10 mg/day), 10.1 points (95% CI: [13.7; 6.5], po0.01)
(escitalopram 20 mg/day) and 7.29 points (95% CI:
[12.3; 2.2], po0.01) (escitalopram 10–20 mg/day)
(Figure 1). For the CGI-S, the corresponding values were
0.55 points (95% CI: [0.79; 0.31], po0.01) (escitalo-
pram 5 mg/day), 0.26 points (95%CI: [0.42; 0.10],
po0.01) (escitalopram 10 mg/day), 0.48 points (95%CI:
[0.64; 0.31], po0.01) (escitalopram 20 mg/day) and
0.29 points (95% CI: [0.51; 0.07], po0.05) (escitalo-
pram 10–20 mg/day) (Figure 2).
3.2. Efﬁcacy at end of 24 weeks of double-blind
treatment
In one study (Lader et al., 2004) although the pre-deﬁned
endpoint was at Week 12, patients were in double-blind
treatment for 24 weeks. At the end of this period, the
estimated treatment difference to placebo on the LSAS was
10.5 points (95% CI: [16.3; 4.7], po0.001) (escitalopram5 mg/day), 7.45 points (95% CI: [13.3; 1.5], po0.05)
(escitalopram 10 mg/day), and 15.1 points (95% CI: [20.9;
9.2], po0.001) (escitalopram 20 mg/day). For the CGI-S, the
corresponding values were 0.42 points (95% CI: [0.71;
0.14], po0.01) (escitalopram 5 mg/day), 0.47 points
(95% CI: [0.76; 0.17], po0.01) (escitalopram 10 mg/day),
0.88 points (95% CI: [1.17; 0.60], po0.001) (escitalo-
pram 20 mg/day).
3.3. Response to treatment at week 12
The estimated treatment difference in response (CGI-I
score r2) at Week 12 is shown in Figure 3. For each
treatment arm in each study, the response rates were 41.2%
(placebo) and 60.8% (escitalopram 5 mg), 37.8% (placebo)
and 48.0% (escitalopram 10 mg), 41.2% (placebo) and 54.9%
(escitalopram 10 mg), 37.8% (placebo) and 54.9% (escitalo-
pram 20 mg), 41.2% (placebo) and 62.0% (escitalopram
20 mg) and 38.6% (placebo) and 54.2% (escitalopram 10–
20 mg). The difference to placebo was signiﬁcant for all
escitalopram doses in each of the three studies, and ranged
from 10.2% to 20.8%. The number-needed-to-treat (NNT) for
CGI−S
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Figure 2 Estimated treatment difference in the Clinical Global Impression-Severity (CGI-S) total score at Week 12 for all 3 studies
shown with 95% conﬁdence intervals. All of the tests for heterogeneity within dose are non-signiﬁcant (p40.05), so the analysis is
based on a ﬁxed effects model. Negative values are in favour of escitalopram, while positive values are in favour of placebo. Patient
numbers are shown for escitalopram (Esc) and placebo (Pbo).
D.S. Baldwin et al.1066response to treatment ranged from 5 to 10 for the individual
studies, with values of 6 (escitalopram 5 mg/day), 9 (esci-
talopram 10 mg/day) and 6 (escitalopram 20 mg/day) in the
meta-analysis.3.4. Withdrawal rates
The total withdrawal rate was 17.3% for all escitalopram
doses, compared with 17.1% for placebo. Withdrawal rates
for different escitalopram doses were as follows: 17.4%
versus 23.5% (5 mg versus placebo), 16.2% versus 16.6%
(10 mg versus placebo) and 16.8% versus 16.6% (20 mg
versus placebo). The withdrawal rate due to adverse events
was 8.1% for all escitalopram doses versus 4.6% for placebo:
withdrawal rates due to adverse events for different
escitalopram doses were as follows: 4.8% versus 6.0%
(5 mg versus placebo), 7.9% versus 4.7% (10 mg versus
placebo) and 9.4% versus 4.7% (20 mg versus placebo). In
the ﬂexible dose study, the overall withdrawal rate was
19.9% versus 18.1% (10–20 mg versus placebo) and thewithdrawal rate due to adverse events was 8.8% versus
4.5% (10–20 mg versus placebo).
4. Discussion
This meta-analysis involved patients with social anxiety
disorder from Europe, North America and Japan who took
part in one of 3 double-blind randomised clinical trials
involving escitalopram. The principal ﬁnding in this meta-
analysis is that escitalopram consistently demonstrated
greater efﬁcacy compared to placebo, as assessed by the
LSAS and the CGI, on a series of endpoint comparisons
involving change in scores from baseline and response rates.
What is the clinical relevance of these results? Reductions
in LSAS scores of at least 20–30% from baseline have been
deﬁned as clinically signiﬁcant (Hansen et al., 2008). In this
meta-analysis, the mean decrease from baseline was 41.0%
(escitalopram 5 mg), 33.0% (escitalopram 10 mg), and 38.6%
(escitalopram 20 mg) versus 27.8% for placebo (Table 1).
This compared with a mean decrease from baseline in the
CGI response
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Figure 3 Estimated treatment difference in the proportion of patients responding to treatment at Week 12 for all 3 studies, based
on a Clinical Global Impression-Improvement (CGI-I) of 1 or 2 (with 95% conﬁdence intervals). The number-needed-to-treat (NNT) is
the inverse of the difference between escitalopram and placebo in the proportion of patients responding to treatment, rounded up
to the nearest integer.
1067Efﬁcacy of escitalopram in the treatment of social anxiety disorderLSAS-J of 33.3% versus 24.4% for placebo in a 10-week SAD
study with ﬂuvoxamine (150–300 mg) (n=273) in Japan
(Asakura et al., 2007).
The estimated treatment differences for escitalopram,
ranging from 4 to 10 points on the LSAS, are statistically
signiﬁcant for all three doses (Figure 1). The response rates
were 37.8–41.2% for placebo (n=537), which was remark-
ably consistent between studies, and 48.0–62.0% for escita-
lopram (n=1061), depending on dose. This corresponds to a
difference to placebo in response rates of over 16%,
considered to be a clinically meaningful difference in
studies in patients with major depression undergoing anti-
depressant treatment (Melander et al., 2008).
In the 12-week open-label phase of a relapse prevention
study with escitalopram 10–20 mg (n=517), LSAS scores
improved by 46.6 points, from 94.8 at baseline to 48.2
(observed cases) (Montgomery et al., 2005). In the open-label phase of this study, 70% of the patients had their dose
increased to escitalopram 20 mg by Week 12. After rando-
misation, both escitalopram doses showed signiﬁcantly
lower relapse rates compared to their corresponding pla-
cebo group. The mean dose at Week 12 in the ﬂexibly-dosed
study of Kasper et al., 2005 was 17.6 mg, indicating that
76% of patients had increased their dose to 20 mg/day
escitalopram.
There are also open-label studies in SAD with escitalo-
pram. In a large (n=158) open-label ﬂexible-dose study
(10–20 mg/day) in Japan (Asakura et al., submitted for
publication), 81.0% of patients completed 52 weeks of
treatment. LSAS-J scores improved from 95.3 at baseline
to 49.9 (FAS, OC) at Week 52 and (56.3 at last assessment
(LOCF, FAS]), with 68.4% of patients increasing their dose
from 10 to 20 mg/day. In a small (n=29) 12-week open-
label study with escitalopram 10–20 mg in patients with
D.S. Baldwin et al.1068treatment-resistant SAD, LSAS scores reduced by 29.2
points, from 62.4 at baseline to 33.2 (mixed model
repeated measures) (Pallanti and Quercioli, 2006). In
another small (n=14) 12-week open-label study with
escitalopram 10–20 mg in patients with SAD, LSAS scores
reduced by 25.8 points, from 83.6 at baseline to 57.8
(Warwick et al., 2012), with a signiﬁcantly greater
improvement in patients with an A10/A10 genotype, which
is associated with increased expression of the dopamine
transporter. In the third small 12-week open-label study
with escitalopram 10–30 mg in patients with SAD (n=39)
and fear of blushing, LSAS scores reduced by 24.2 points,
from 76.8 at baseline to 52.6, and 20 of 28 patients (71.4%)
responded (CGI-I r2, FAS, OC) to treatment (Pelissolo and
Moukheiber, 2013). And in a 12-week open-label study with
escitalopram 10–20 mg in children with SAD, 13 of 20
patients (65.0%) responded (CGI-I r2) to treatment
(Isolan et al., 2007). In spite of the possibility of expecta-
tion effects in these open-label studies (Bandelow et al.,
2015), the mean improvement from baseline is similar in
magnitude to those found in the randomised controlled
trials included in this meta-analysis (Table 1).
In a comparison of pharmacological and psychological
treatments based on the difference between pre-post and
treated versus control effect sizes, medications have been
associated with a signiﬁcantly higher average pre-post
effect size than psychotherapies (Bandelow et al., 2015).
The choice of a pharmacotherapy should be made on the
basis of efﬁcacy as well as on possible side effects, contra-
indications and interactions (Baldwin et al., 2014). The total
withdrawal rate for patients treated with escitalopram in
the three SAD studies included in this meta-analysis was at
placebo level, while the adverse event withdrawal rate for
all escitalopram doses was 4.8–9.4% versus placebo (4.5–
6.0%).
A limitation of this meta-analysis is the small number of
randomised controlled studies, all of which were sponsored
by the manufacturer of escitalopram. As a result of reg-
ulatory and safety requirements, patients with another
psychiatric disorder were excluded, as were those with
depressive symptoms. Very few patients with an ethnicity
other than Caucasian or Japanese were treated in these
studies. Thus, these patients may not be representative of
those seen in actual clinical practice.
In conclusion, in this meta-analysis all doses of escitalo-
pram (5, 10 and 20 mg/day) had signiﬁcantly greater
efﬁcacy versus placebo, as assessed by the LSAS and the
CGI on a series of endpoint comparisons involving change in
efﬁcacy scores from baseline and response rates. Given its
favourable tolerability proﬁle based on withdrawals due to
adverse events, these results suggest that escitalopram has
a good beneﬁt-risk ratio.Contributors
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